In veterinary medicine, there have been different experiences with the plasmid DNA vaccination. In this area and with the hypothesis to demonstrate the effectiveness of different plasmids encoding porcine respiratory and reproductive syndrome (PRRS), five DNA vaccines against PRRS were evaluated for their innocuity and efficacy in pigs. Eighteen animals were divided into five groups which were injected with five (A, B, C, D, E) different DNA vaccines. Albeit, none of the proposed vaccines were able to protect the animals against PRRS virus. Only vaccines A and B were able to reduce the clinical signs of the infection. ELISA IgM were detected 30 days after the first vaccination in the pigs injected by Vaccine A or B. ELISA IgG were detected 90 days after the first vaccination in the pigs injected by Vaccine B or C. Neutralizing antibody were detected Post Challenge Days 61 (PCD) in all groups. In the pigs inoculated with Vaccine C, IFN-g were detected 90 days after first vaccination, and after challenge exposure they increased. In the other groups, the IFN-g were detected after challenge infection. Pigs injected with each of the vaccines A, B, C, D and E showed a significantly higher level of CD4 ？CD8 + lymphocytes ( p < 0.001) after infection in comparison with their controls.
References
[1]
Cavanagh, D. Nidovirales: A new order comprising Coronaviridae and Arteriviridae. Arch. Virol. 1997, 142, 629–633.
[2]
Costers, S.; Lefebvre, D.J.; van Doorsselaere, J.; Vanhee, M.; Delputte, P.L.; Nauwynck, H.J. GP4 of porcine reproductive and respiratory syndrome virus contains a neutralizing epitope that is susceptible to immunoselection in vitro. Arch. Virol. 2010, 155, 371–378, doi:10.1007/s00705-009-0582-7.
[3]
Vanhee, M.; van Breedman, W.; Costers, S.; Geldhof, M.; Noppe, Y.; Nauwynck, H. Characterization of antigenic regions in the porcine reproductive and respiratory syndrome virus by the use of peptide-specific serum antibodies. Vaccine 2011, 29, 4794–4804, doi:10.1016/j.vaccine.2011.04.071.
[4]
Li, J.; Murthaugh, M.P. Dissociation of porcine reproductive and respiratory syndrome virus neutralization from antibodies specific to major envelope protein surface epitopes. Virology 2012, 433, 367–376, doi:10.1016/j.virol.2012.08.026.
[5]
Ren, X.; Wang, M.; Yin, J.; Ren, Y.; Li, G. Heterologous expression of fused genes encoding the glycoprotein 5 from PRRSV: A way for producing functional protein in prokaryotic microorganism. J. Biotechol. 2010, 147, 130–135, doi:10.1016/j.jbiotec.2010.03.013.
Kwang, J.; Zuckermann, F.; Ross, J.; Yang, S.; Osorio, F.; Liu, W.; Low, S. Antibody and cellular immune responses of swine following immunisation with plasmid DNA encoding the PRRS ORF’s 4,5,6 and 7. Res. Vet. Sci. 1999, 67, 199–201, doi:10.1053/rvsc.1998.0291.
[8]
Li, G.; Shi, N.; Suo, S.; Cui, J.; Zarlenga, D.; Ren, X. Vaccination of mice with ORF 5 plasmid DNA of PRRSV; enanched effects by co-immunizing with porcine IL-15. Immunol. Invest. 2012, 41, 231–248, doi:10.3109/08820139.2011.614306.
[9]
Amici, A.; Smorlesi, A.; Noce, G.; Santoni, G.; Cappelletti, P.; Capparuccia, L.; Coppari, R.; Lucciarini, R.; Petrelli, C.; Provinciali, M. DNA vaccination with full-lenght or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 2000, 7, 703–706, doi:10.1038/sj.gt.3301151.
[10]
Rovero, S.; Amici, A.; di Carlo, E.; Bei, R.; Nanni, P.; Quaglino, E.; Porcedda, P.; Boggio, K.; Smorlesi, A.; Lollini, P.L.; et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carciogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 2000, 165, 5133–5142.
[11]
Bachmair, A.; Varshavsky, A. The degradation signal in a short-lived protein. Cell 1989, 56, 1019–1032, doi:10.1016/0092-8674(89)90635-1.
[12]
Bachmair, A.; Finley, D.; Varshavsky, A. In vivo half-life of a protein as a function of its amino-terminal residue. Science 1986, 234, 179–186.
[13]
Kozak, M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 1987, 196, 947–950, doi:10.1016/0022-2836(87)90418-9.
[14]
Revilla-Fernandez, S.; Wallner, B.; Truschner, K.; Benczak, A.; Brem, G.; Schmoll, F.; Mueller, M.; Steinborn, M. The use of endogenous references RNAs for qualitative and quantitative detection of PRRSV in porcine semen. J. Vir. Method 2005, 126, 21–30, doi:10.1016/j.jviromet.2005.01.018.
[15]
Yoon, I.J.; Joo, H.S.; Goyal, S.M.; Molitor, T.W. A modified serum neutralization test for the detection of antibody to porcine respiratory and reproductive syndrome virus in swine sera. J. Vet. Diagn. Invest. 1994, 6, 289–292.
[16]
Borghetti, P.; de Angelis, E.; Saleri, R.; Cavalli, V.; Cacchioli, A.; Corradi, A.; Mocheggiani, E.; Martelli, P. Peripheral T lymphocyte changes in neonatal piglets: Relationship with growth hormone (GH), prolacin (PRL) and cortisol changes. Vet. Immunol. Immunopathol. 2006, 110, 17–25, doi:10.1016/j.vetimm.2005.09.001.
[17]
Zhang, X.; Li, G.; Gao, L.; Mu, L.; Zhang, L.; Cong, Y.; Ding, Z. Positive inductive effect of IL-18 on virus-specific immune responses induced by PRRSV-GP5 DNA vaccine in swine. Res. Vet. Sci. 2013, 94, 346–353, doi:10.1016/j.rvsc.2012.09.011.
[18]
Zhou, L.; Yang, H.C. Porcine reproductive and respiratory syndrome in China. Virus Res. 2010, 154, 31–37, doi:10.1016/j.virusres.2010.07.016.
[19]
Meng, X.J. Heterogeneity of porcine reproductive and respiratory syndrome virus: Implications for current vaccine efficacy and future vaccine development. Vet. Microbiol. 2000, 74, 309–329, doi:10.1016/S0378-1135(00)00196-6.
[20]
Opriessnig, T.; Halbur, P.G.; Yoon, K.J.; Pogranichniy, R.M.; Harmon, K.M.; Evans, R.; Key, K.F.; Pllares, F.J.; Thomas, P.; Meng, X.J. Comparision of molecular and biological syndrome virus (PRRSV) vaccine (Ingelvac PRRS MLV), the parent strain of the vaccine (ATCC VR2332), (ATCC VR2385), and two recent field isolates of PRRSV. Virology 2002, 76, 11837–11844, doi:10.1128/JVI.76.23.11837-11844.2002.
[21]
Scrotti, M.; Prieto, C.; Alvarez, E.; Simarro, I.; Castro, J.M. Failure of an inactivated vaccine against porcine reproductive and respiratory syndrome to protect gilts against a heterologous challenge with PRRSV. Vet. Rec. 2007, 161, 809–813.
[22]
Geldhof, M.F.; Vanhee, M.; van Breedam, W.; Doorsselaere, J.V.; Karniychuk, U.U.; Nauwynck, H. Comparision of the efficacy of autogenous inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges. BMC Vet. Res. 2012, doi:10.1186/1746-6148-8-182.
[23]
Babiuk, L.A.; Pontarollo, R.; Babiuk, S.; Loehr, B.; van Drunen Little-van den Hurk, S. Induction of immune responses by vaccines in large animals. Vaccine 2003, 21, 649–658, doi:10.1016/S0264-410X(02)00574-1.
[24]
Pontarollo1, R.A.; Babiuk, L.A.; Hecker, R.; van Drunen Little-van den Hurk, S. Augumentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enanched plasmid vectors. J. Gen. Virol. 2002, 83, 2973–2981.
[25]
Jiang, W.; Jiang, P.; Wang, X.; Li, Y.; Du, Y.; Wang, X. Enhanced immuneresponses of mice inoculated recombinant adenovirus expressing GP5 by fusion with GP3 and/or GP4 of PRRS virus. Virus Res. 2008, 136, 50–57, doi:10.1016/j.virusres.2008.04.016.
Zhang, X.; Wang, X.; Mu, L.; Ding, Z. Immune responses in pigs induced by recombinant DNA vaccine co-expressing swine IL-18 and membrane protein of porcine reproductive and respiratory syndrome virus. Int. J. Mol. Sci. 2012, 13, 5715–5728, doi:10.3390/ijms13055715.
[28]
Du, Y.; Qi, J.; Lu, Y.; Wu, J.; Yoo, D.; Liu, X.; Zhang, X.; Li, J.; Sun, D.; Cong, X.; et al. Evaluation of a DNA vaccine candidate co-expressing GP3 and GP5 of porcine reproductive and respiratory syndrome virus (PRRSV) with interferon α/γ in immediate and long-lasting protection against HP-PRRSV challenge. Virus Genes 2012, 45, 474–487, doi:10.1007/s11262-012-0790-1.
[29]
Petrini, S.; Ramadori, G.; Corradi, A.; Borghetti, P.; Lombardi, G.; Villa, R.; Bottarelli, E.; Guercio, A.; Amici, A.; Ferrari, M. Evaluation of safety and efficacy of DNA vaccines against bovine herpesvirus-1 (BoHV-1) in calves. Comp. Immnol. Microbiol. Infect. Dis. 2011, 34, 3–10, doi:10.1016/j.cimid.2009.09.004.
[30]
Cano, J.P; Dee, S.A.; Murtaugh, M.P.; Pijoan, C. Impact of a modified-live porcine reproductive and respiratory syndrome virus vaccine intervention on a population of pigs infected with a heterologous isolate. Vaccine 2007, 25, 4383–4391.
[31]
Scrotti, M.; Prieto, C.; Simarro, I.; Castro, J.M. Reproductive performance of gilts following vaccination and subsequent heterologous challenge with European strains of porcine reproductive and respiratory syndrome virus. Theriogenology 2006, 66, 1884–1893, doi:10.1016/j.theriogenology.2006.04.043.
[32]
Quan, Z.; Qin, Z.G.; Zhen, W.; Feng, X.Z.; Hong, J.; Fei, Z.H. Plasmid containing CpG oligodeoxynucleotides can augment the immune responses of pigs immunized with porcine reproductive and respiratory syndrome killed virus vaccine. Vet. Immunol. Immunopathol. 2010, 136, 257–264, doi:10.1016/j.vetimm.2010.03.015.
[33]
Chia, M.-Y.; Hsiao, S.-H.; Chan, H.-T.; Do, Y.-Y.; Huang, P.L.; Chang, H.W.; Tsai, Y.C.; Lin, C.M.; Pang, V.F.; Jeng, C.R. The immunogenicity of DNA constructs co-expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus conjugated by GPGP linker in pigs. Vet. Microbiol. 2010, 146, 189–199, doi:10.1016/j.vetmic.2010.05.007.
[34]
Hu, J.; Zhang, C. Porcine reproductive and respiratory syndrome virus vaccines: Current status and strategies to a universal vaccine. Transbound. Emerg. Dis. 2012, doi:10.1111/tbed.12016.
[35]
Yang, L.; Frey, M.L.; Yoon, K.J.; Zimmerman, J.J.; Platt, K.B. Categorization of North American porcine reproductive and respiratory syndrome virus: Epitopic profiles of the N M GP5 and GP3 proteins and susceptibility to neutralization. Arch. Virol. 2000, 145, 1599–1619, doi:10.1007/s007050070079.
[36]
Lopez, O.J.; Osorio, F.A. Role of neutralizing antibodies in PRRSV protective immunity. Vet. Immunol. Immunopathol. 2004, 102, 155–163, doi:10.1016/j.vetimm.2004.09.005.
[37]
Ostrowski, M.; Galeota, J.A.; Jar, A.M.; Platt, K.B.; Osorio, F.A.; Lopez, O.J. Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain. J. Virol. 2002, 76, 4241–4250, doi:10.1128/JVI.76.9.4241-4250.2002.
[38]
Plagemann, P.G. The primary GP5 neutralization epitope of North American isolates of porcine reproductive and respiratory syndrome virus. Vet. Immunol. Immunopathol. 2004, 102, 263–275, doi:10.1016/j.vetimm.2004.09.011.
[39]
Foss, D.L.; Zilliox, M.J.; Meier, W.; Zuckermann, F.; Murtaugh, M.P. Adjuvant danger signals increase the immune response to porcine reproductive and respiratory syndrome virus. Viral Immunol. 2002, 15, 557–566, doi:10.1089/088282402320914502.
[40]
Darwich, L.; Diaz, I.; Mateu, E. Certainties, dobts and hypotheses in porcine reproductive and respiratory syndrome virus immunobiology. Virus Res. 2010, 154, 123–132, doi:10.1016/j.virusres.2010.07.017.
